SCHEDULE: MAK Capital Discloses 5.3% Stake in Evotec SE

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly reported a 5.3% beneficial ownership stake in Evotec SE, totaling 9,386,434 ordinary shares.

Summary

• MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons beneficially own 9,386,434 Ordinary Shares of Evotec SE.
• This ownership represents 5.3% of Evotec SE's outstanding Ordinary Shares.
• The calculation is based on 177,778,907 Ordinary Shares outstanding as of January 9, 2026, as reported by Evotec SE on its website.
• The filing indicates shared voting and dispositive power over all 9,386,434 shares.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Evotec SE.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by an institutional investor is generally a positive signal, indicating confidence in the company's value proposition without suggesting immediate operational changes or challenges.

Positives

• A significant institutional investor, MAK Capital, has taken a substantial 5.3% stake in Evotec SE, signaling confidence in the company.
• The investment is classified as passive, indicating a long-term holding strategy without immediate intent to influence control.

Risks

• The filing itself does not detail company-specific risks for Evotec SE.
• The investment is subject to general market risks and risks inherent to Evotec SE's business operations.

Future Outlook

The filing does not provide any forward-looking statements or guidance from Evotec SE or the reporting persons regarding the company's future performance or strategic direction, beyond the passive nature of the investment.

Industry Context

This filing indicates a significant institutional investment in Evotec SE, a company likely operating in the biotechnology or pharmaceutical sector given its name. Such a substantial stake by a capital fund can be viewed as a vote of confidence in the company's long-term prospects within its industry, potentially attracting further investor interest.

Comparison to Industry Standards

• A 5.3% stake is a notable position for a single investment group in a publicly traded company.
• While the filing explicitly states the investment is passive and not intended to influence control, such a significant holding by an entity like MAK Capital Fund LP, a Bermuda limited partnership, and MAK Capital One L.L.C., a Delaware limited liability company, led by Michael A. Kaufman, suggests a strategic long-term view.
• This level of ownership is common for institutional investors seeking exposure to specific sectors or companies without engaging in activist roles, aligning with typical passive investment strategies seen across various industries.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive indicator of the company's value and future prospects, potentially increasing investor confidence.
• Management: The passive nature of the investment suggests no immediate pressure for strategic or operational changes from this particular shareholder group.

Key Dates

Recommendation

This filing is a disclosure of a passive beneficial ownership stake and does not contain new operational or financial information about Evotec SE that would warrant a change in investment strategy. The presence of a significant institutional investor like MAK Capital can be seen as a positive long-term signal, reinforcing a 'hold' position for existing investors, but it doesn't provide a direct catalyst for 'buy' or 'sell' based solely on this disclosure.

Keywords

Evotec SE, MAK Capital, Beneficial Ownership, Schedule 13G, Ordinary Shares, Biotechnology, Pharmaceuticals, Investment, Institutional Investor, Passive Investment